Curr Opin Immunol. 2026 Mar 10;100:102749. doi: 10.1016/j.coi.2026.102749. Online ahead of print.
ABSTRACT
Graft versus host disease (GVHD) is one of the major complications of allogeneic hematopoietic cell transplantation (allo-HCT), contributing significantly to post-transplant morbidity and mortality. Anti-thymocyte globulin (ATG) is a widely used GVHD prophylaxis in combination with a calcineurin inhibitor and an antimetabolite. Post-transplant cyclophosphamide (PTCy) has been a milestone in haploidentical transplantation, and its use has expanded to allo-HCT performed from matched related and unrelated donors with notable success. In this review, we discuss how post-transplantation outcomes can be optimized through a combination of ATG with PTCY. We summarize the biological rationale, current clinical evidence, and remaining uncertainties regarding this dual in vivo T-cell depletion strategy, highlighting its potential to enhance GVHD control, reduce immunosuppressive burden, and improve survival across different donor settings.
PMID:41812347 | DOI:10.1016/j.coi.2026.102749